Table 2 Outcomes compared between infected and non-infected cases
Control | Late acute hematogenous | Total | ||
|---|---|---|---|---|
(N = 20) | (N = 10) | (N = 30) | p-value | |
Age (years) | 0.441 | |||
Mean (SD) | 70.70 (9.76) | 72.60 (9.47) | 71.33 (9.54) | |
Median (Q1, Q3) | 70.0 (67.0, 73.5) | 75.5 (64.0, 80.0) | 71.0 (67.0, 80.0) | |
Min., Max | 51.0, 91.0 | 56.0, 82.0 | 51.0, 91.0 | |
KSS | 0.291 | |||
Mean (SD) | 82.10 (10.70) | 84.10 (17.87) | 82.77 (13.23) | |
Median (Q1, Q3) | 84.0 (76.0, 91.0) | 91.0 (67.0, 96.0) | 85.0 (75.0, 92.0) | |
Min., Max | 57.0, 100.0 | 47.0, 100.0 | 47.0, 100.0 | |
Follow-up (years) | 0.741 | |||
Mean (SD) | 8.95 (2.96) | 8.50 (2.46) | 8.80 (2.77) | |
Median (Q1, Q3) | 8.5 (6.5, 11.0) | 8.0 (7.0, 11.0) | 8.0 (7.0, 11.0) | |
Min., Max | 4.0, 15.0 | 5.0, 12.0 | 4.0, 15.0 | |
Gender | 1.000 | |||
Male | 4 (20.0%) | 2 (20.0%) | 6 (20.0%) | |
Female | 16 (80.0%) | 8 (80.0%) | 24 (80.0%) |